Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Revenue (2017 - 2025)

Puma Biotechnology's Revenue history spans 9 years, with the latest figure at $75.5 million for Q4 2025.

  • For Q4 2025, Revenue rose 27.72% year-over-year to $75.5 million; the TTM value through Dec 2025 reached $228.4 million, down 0.91%, while the annual FY2025 figure was $228.4 million, 0.91% down from the prior year.
  • Revenue reached $75.5 million in Q4 2025 per PBYI's latest filing, up from $54.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $98.2 million in Q1 2021 to a low of $43.8 million in Q1 2024.
  • Average Revenue over 5 years is $59.9 million, with a median of $55.0 million recorded in 2021.
  • Peak YoY movement for Revenue: surged 91.67% in 2021, then crashed 53.41% in 2022.
  • A 5-year view of Revenue shows it stood at $55.4 million in 2021, then skyrocketed by 58.33% to $87.6 million in 2022, then decreased by 17.65% to $72.2 million in 2023, then dropped by 18.15% to $59.1 million in 2024, then grew by 27.72% to $75.5 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Revenue are $75.5 million (Q4 2025), $54.5 million (Q3 2025), and $52.4 million (Q2 2025).